Revenue from Contract with Customer, Excluding Assessed Tax of Lexaria Bioscience Corp. from 30 Nov 2017 to 30 Nov 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Lexaria Bioscience Corp. quarterly and annual Revenue from Contract with Customer, Excluding Assessed Tax in USD history and change rate from 30 Nov 2017 to 30 Nov 2024.
  • Lexaria Bioscience Corp. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 30 Nov 2024 was $183,923, a 22% increase year-over-year.
  • Lexaria Bioscience Corp. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2024 was $464,278, a 105% increase from 2023.
  • Lexaria Bioscience Corp. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $226,208, a 11% decline from 2022.
  • Lexaria Bioscience Corp. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $255,397, a 65% decline from 2021.
Source SEC data
View on sec.gov
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)

Lexaria Bioscience Corp. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $183,923 +$32,645 +22% 01 Sep 2024 30 Nov 2024 10-Q 10 Jan 2025 2025 Q1
Q4 2023 $151,278 +$53,543 +55% 01 Sep 2023 30 Nov 2023 10-Q 10 Jan 2025 2025 Q1
Q4 2022 $97,735 +$83,855 +604% 01 Sep 2022 30 Nov 2022 10-Q 12 Jan 2024 2023 Q1
Q4 2021 $440,962 $13,880 -$281,776 -95% 01 Sep 2021 30 Nov 2021 10-Q/A 18 Jan 2023 2023 Q1
Q3 2021 $722,738 $31,021 -$269,218 -90% 01 Jun 2021 31 Aug 2021 10-K 28 Nov 2022 2022 FY
Q2 2021 $991,956 $204,055 +$167,632 +460% 01 Mar 2021 31 May 2021 10-Q 15 Jul 2021 2021 Q3
Q1 2021 $824,324 $192,006 +$154,457 +411% 01 Dec 2020 28 Feb 2021 10-Q 14 Apr 2021 2021 Q2
Q4 2020 $669,867 $295,656 +$285,324 +2762% 01 Sep 2020 30 Nov 2020 10-Q 14 Jan 2021 2021 Q1
Q3 2020 $384,543 $300,239 +$175,118 +140% 01 Jun 2020 31 Aug 2020 10-K 15 Oct 2020 2020 FY
Q2 2020 $209,425 $36,423 -$23,508 -39% 01 Mar 2020 31 May 2020 10-Q 15 Jul 2021 2021 Q3
Q1 2020 $232,933 $37,549 +$22,200 +145% 01 Dec 2019 29 Feb 2020 10-Q 14 Apr 2021 2021 Q2
Q4 2019 $210,733 $10,332 -$11,877 -53% 01 Sep 2019 30 Nov 2019 10-Q 14 Jan 2021 2021 Q1
Q3 2019 $222,610 $125,121 +$28,767 +30% 01 Jun 2019 31 Aug 2019 10-K 15 Oct 2020 2020 FY
Q2 2019 $193,843 $59,931 -$80,409 -57% 01 Mar 2019 31 May 2019 10-Q 29 Jun 2020 2020 Q3
Q1 2019 $274,252 $15,349 -$156,609 -91% 01 Dec 2018 28 Feb 2019 10-Q 03 Apr 2020 2020 Q2
Q4 2018 $430,861 $22,209 -$2,426 -9.8% 01 Sep 2018 30 Nov 2018 10-Q 09 Jan 2020 2020 Q1
Q3 2018 $433,287 $96,354 01 Jun 2018 31 Aug 2018 10-K 14 Nov 2019 2019 FY
Q2 2018 $140,340 01 Mar 2018 31 May 2018 10-Q 08 Jul 2019 2019 Q3
Q1 2018 $171,958 01 Dec 2017 28 Feb 2018 10-Q 15 Apr 2019 2019 Q2
Q4 2017 $24,635 01 Sep 2017 30 Nov 2017 10-Q 11 Jan 2019 2019 Q1

Lexaria Bioscience Corp. Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $464,278 +$238,070 +105% 01 Sep 2023 31 Aug 2024 10-K 26 Nov 2024 2024 FY
2023 $226,208 -$29,189 -11% 01 Sep 2022 31 Aug 2023 10-K 26 Nov 2024 2024 FY
2022 $255,397 -$467,341 -65% 01 Sep 2021 31 Aug 2022 10-K 20 Nov 2023 2023 FY
2021 $722,738 +$338,195 +88% 01 Sep 2020 31 Aug 2021 10-K 28 Nov 2022 2022 FY
2020 $384,543 +$161,933 +73% 01 Sep 2019 31 Aug 2020 10-K 15 Oct 2020 2020 FY
2019 $222,610 -$210,677 -49% 01 Sep 2018 31 Aug 2019 10-K 15 Oct 2020 2020 FY
2018 $433,287 01 Sep 2017 31 Aug 2018 10-K 14 Nov 2019 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.